Fig. 7: Reversal of chemotherapy resistance in mouse models of chemoresistant cancer.
From: Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance
a Spot blot analysis of MITOx20, MITOx30, and Control-30 prior to (0 h) or after incubation with serum (3 or 6 h) using an antibody specific for the N-terminus of MCJ. b MCJ-deficient MMTV-PyMT mice were treated with doxorubicin alone (Dox, n = 5), MITOx30 alone (n = 4), or doxorubicin in combination with Control-30 (n = 4), MITOx20 (n = 6), or MITOx30 (n = 5) every other day for 12 d. Change in tumor volume over time during treatment relative to the initial tumor size is shown. p = 0.0001. c NSG mice with NCI/ADR-RES cell xenografts were treated with doxorubicin alone or in combination with MITOx20 or MITOx30 every other day for 8 d (n = 6). Change in tumor volumes over time during treatment relative to the initial tumor size is shown. p = 0.0001. d NSG mice (n = 4 per group) with NCI/ADR-RES cell xenografts were treated with doxorubicin alone or in combination with Control-30 as in (c). For b–d repeated measures analysis of variance was used to examine the trajectory of tumor volume over time, and statistical significance for all post hoc tests were subject to Bonferroni correction to control for multiple comparisons. Mean ± SEM provided for all figures.
